Primary hyperparathyroidism: Diagnosis, evaluation, and treatment

Current Opinion in Endocrinology and Diabetes

Volumn 11, Issue 6, 2004, Pages 345-352

  Bilezikian, John P ^a   Rubin, Mishaela ^a   Silverberg, Shonni J ^a  

^a Columbia University ^*  (United States)

Author keywords

Hypercalcemia; Parathyroid hormone; Parathyroidectomy; Primary hyperparathyroidism

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCIUM; CINACALCET; PARATHYROID HORMONE; R 568; UNCLASSIFIED DRUG;

CALCIUM BLOOD LEVEL; CLINICAL ASSESSMENT; DIAGNOSTIC PROCEDURE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE METABOLISM; HUMAN; HYPERCALCEMIA; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; REVIEW; SCREENING;

EID: 28744447058     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000144035.12532.a7     Document Type: Review

References (91)

1. Lepage R, Roy L, Brossard JH, et al.: A non (1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 2004, 44:805-809.
2. Gao P, Scheibel S, D'Amour P, et al.: Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84. Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001, 16:4:605-614.
3. John MR, Goodman WG, Gao P, et al.: A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurement in renal failure. J Clin Endocrinol Metab 1999, 84:4287-4290.
4. Silverberg SJ, Brown I, LoGerfo P, et al.: Clinical utility of an immunoradiometric assay for whole PTH (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88:4725-4730. This report compares the newest of the immunoassays for PTH in which only the full-length molecule is detected with several older assays among a cohort of patients with primary hyperparathyroidism.
5. Kifor O, Moore FD Jr, Delaney M, et al.: a syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab 2003, 88:60-72. In this report, endogenously appearing, inactivating antibodies against the calcium receptor give rise to a syndrome very much like familial hypocalciuric hypercalcemia. Characteristics of these patients as well as the anti-calcium receptor antibody are presented.
6. Pallais JC, Kifor O, Chen Y-B, et al.: Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med 2004, 351:362-369. Similar to [5], this report provides convincing evidence that antibodies directed against the calcium receptor can lead to a syndrome of acquired hypocalciuric hypercalcemia.
7. Maruani G, Hertig A, Paillard M, et al.: Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003, 88:4641-4648. Patients with primary hyperparathyroidism in whom the serum calcium level is consistently normal are beginning to be described. This paper is one of the first to characterize a group of these patients.
8. Silverberg SJ, Bilezikian JP: "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab 2003, 88:5348-5352. Similar to [7], this report is one of the first to describe a syndrome in which patients with primary hyperparathyroidism have normal serum calcium levels. The entity, normocalcemic primary hyperparathyroidism, is now being seen more and more commonly. Reasons for this and concepts related to the evolution of the primary hyperparathyroid state are described in this article.
9. Rao DS, Wilson RJ, Kleerekoper M, et al.: Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 1988, 67:1294-1298.
10. Silverberg SJ, Gartenberg F, Jacobs TP, et al.: Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995, 80:723-238.
11. Bilezikian JP, Silverberg SJ, Shane E, et al.: Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991, 6(suppl I):585-589.
12. Silverberg SJ, Shane E, Delacruz L, et al.: Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989, 4:283-291.
13. Silverberg SJ, Locker FG, Bilezikian JP: Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 1996, 81:4007-4012.
14. Parisien M, Silverberg SJ, Shane E, et al.: The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990, 70:930-938.
15. Parfitt AM: Surface specific bone remodeling in health and disease. In Clinical Disorders of Bone and Mineral Metabolism, edited by Kleerekoper M. New York: Mary Ann Liebert, 1989:7-14.
16. Parisien M, Cosman F, Mellish RWE, et al.: Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J Bone Miner Res 1995, 10:1393-1399.
17. Parisien M, Mellish RWE, Silverberg SJ, et al.: Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular and strut analysis. J Bone Miner Res 1992, 7:913-920.
18. Dempster DW, Parisien M, Silverberg SJ, et al.: On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999, 84:1562-1566.
19. Dauphine RT, Riggs BL, Scholz DA: Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975, 83:365-367.
20. Kochesberger G, Buckley NJ, Leight GS, et al.: What is the clinical significance of bone loss in primary hyperparathyroidism. Arch Intern Med 1987, 147:1951-1953.
21. Wilson RJ, Rao S, Ellis B, et al.: Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988, 109:959-962.
22. Larsson K, Ljunghall S, Krusemo UB, et al.: The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 1993, 234:585-593.
23. Kenny AM, MacGillivray DC, Pilbeam CC, et al.: Fracture incidence in post-menopausal women with primary hyperparathyroidism. Surgery 1995, 118:109-114.
24. Khosla S, Melton LJ, Wermers RA, et al.: Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999, 14:1700-1707.
25. Adami S, Braga V, Squaranti R, et al.: Bone measurements in asymptomatic primary hyperparathyroidism. Bone 1998, 22:565-570.
26. Chen Q, Kaji H, Iu M-F, et al.: Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 2003, 88:4655-4658. Besides affecting bone mineral density, it is now known that PTH has important effects on bone size. Using peripheral quantitative CT, Chen et al. provide data confirming the idea, presented first by Adami et al. [25], that PTH affects cross-sectional areas of bone and bone density.
27. Parfitt AM: Parathyroid hormone and periosteal bone expansion. J Bone Miner Res 2002, 17:1741-1743.
28. Bilezikian JP: Bone strength in primary hyperparathyroidism. Osteoporos Int 2003, 14(suppl 5):5113-5117. Because PTH affects a number of different parameters that help to define bone strength, it is not clear whether bone density alone can accurately predict fracture risk in primary hyperparathyroidism. In this paper, Bilezikian considers these other factors.
29. Klugman VA, Favus M, Pak CYC: Nephrolithiasis in primary hyperparathyroidism. In The Parathyroids: Basic and Clinical Concepts, edited by Bilezikian JP. New York: Academic Press, 2001:437-450.
30. Silverberg SJ: Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res 2003, 17(suppl 2):N117-N125. In asymptomatic primary hyperparathyroidism, by far the most common presentation of the disease in the developed world, guidelines call for evaluation of the skeleton and the kidney, the two most common target organs in this disorder. In this paper, Silverberg covers other potential target organs in primary hyperparathyroidism and their potential for involvement even in asymptomatic disease.
31. Patten BM, Bilezikian JP, Mallette LE, et al.: The neuromuscular disease of hyperparathyroidism. Ann Intern Med 1974, 80:182-194.
32. Turken SA, Cafferty M, Silverberg SJ, et al.: Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989, 87:553-557.
33. Joborn C, Hetta J, Johansson H, et al.: Psychiatric morbidity in primary hyperparathyroidism. World J Surg 1998, 2:476-481.
34. Solomon BL, Schaaf M, Smallridge RC: Psychologic symptoms before and after parathyroid surgery. Am J Med 1994, 96:101-106.
35. Burney RE, Jones KR, Christy B, et al.: Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels. Surgery 1999, 125:608-614.
36. Talpos GB, Bone HG, Kleerekoper M, et al.: Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 2000, 128:1013-1020.
37. Brown GG, Preisman RC, Kleerekoper MD: Neurobehavioral symptoms in mild hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Med J 1987, 35:211-215.
38. Lafferty FW: Primary hyperparathyroidism: changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med 1981, 141:1761-1766.
39. Symons C, Fortune F, Greenbaum RA, et al.: Cardiac hypertrophy, hypertrophic cardiomyopathy and hyperparathyroidism-an association. Br Heart J 1985, 54:539-542.
40. Stefenelli T, Mayr H, Bergler-Klein J, et al.: Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993, 95:197-202.
41. Stefenelli T, Mayr H, Berger-Klein J, et al.: Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993, 95:197-202.
42. Barletta G, De Feo ML, Del Bene R, et al.: Cardiovascular effects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild hyperparathyroidism. J Clin Endocrinol Metab 2000, 85:1815-1821.
43. Smith JC, Page MD, Wheeler MH, et al.: Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85:3515-3519.
44. Rubin MR, Bilezikian JP, Silverberg SJ: Vascular stiffness is increased in patients with primary hyperparathyroidism. J Bone Miner Res 2002, 17:S381.
45. Harinarayan DV, Gupta N, Kochupillai N: Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol 1995, 43:351-358.
46. Meng XW, Xing XP, Liu SQ, et al.: The diagnosis of primary hyperparathyroidism-analysis of 134 cases. Acta Acad Med Sin 1994, 16:116-122.
47. Luong KVQ, Nguyen LTH: Coexisting hyperthyroidism and hyperparathyroidism with vitamin D deficient osteomalacia in a Vietnamese immigrant. Endocr Pract 1996, 2:250-254.
48. Lumb GA, Stanbury SW: Parathyroid function in vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974, 54:833-839.
49. Silverberg SJ, Shane E, Dempster DW, et al.: Vitamin D deficiency in primary hyperparathyroidism. Am J Med 1999, 107:561-567.
50. Palmer M, Adami HO, Bergstrom R, et al.: Mortality after surgery for primary hyperparathyroidism. A follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987, 102:1-7.
51. Palmer M, Adami HO, Bergstrom G, et al.: Survival and renal function in untreated hypercalcemia. Lancet 1987, 1:59-62.
52. Ogard CG, Engholm G, Almdal TP, et al.: Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977-1993 in Denmark. World J Surg 2004,:108-111. Accurate mortality figures are hard to confirm in this disorder because epidemiologic databases are uncommon. In this paper, Ogard et al. present data from a well-characterized database from Denmark, suggesting that mortality is increased in this disorder. Whether these observations are applicable to other cohorts of patients with primary hyperparathyroidism in whom signs and symptoms may differ is not clear.
53. Wermers RA, Khosla S, Atkinson EJ, et al.: Survival after the diagnosis of hyperparathyroidism. Am J Med 1998, 104:115-122.
54. National Institutes of Health: Consensus development conference statement on primary hyperparathyroidism. J Bone Miner Res 1991, 6:s9-s13.
55. st century. J Bone Miner Res 2002, 17(suppl 2):N2-N11
56. (also published in J Clin Endocrinol Metab 2002, 87:5353-5361).
57. Consensus Development Task Force on Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism: Standards and guidelines for diagnosis and management in Canada. Endocr Pract 2003, 9:400-405. After the publication emanating from the Workshop on Asymptomatic Primary Hyperparathyroidism [55], this paper follows with a consideration of how these guidelines are applicable to Canadians and their health system.
58. Clark OH: How should patients with primary hyperparathyroidism be treated? J Clin Endocrinol Metab 2003, 88:3011-3014. This is an insightful editorial written by a prominent parathyroid surgeon.
59. Saint MO, Cogliandolo A, Pidoto RR, et al.: Prospective evaluation of ultrasonography plus MIBI scintigraphy in selecting patients with primary hyperparathyroidism for unilateral neck exploration under local anesthesia. Am J Surg 2004, 187:388-393. With advances in imaging, this paper describes how preoperative localization can help to decide which kind of parathyroid surgery to perform.
60. Udelsman R, Donovan POI, Sokoll LT: One hundred consecutive minimally invasive parathyroid explorations. Ann Surg 2000, 232:331-339.
61. Hoyanyi J, Duffek L, Szlavik R, et al.: Parathyroid surgical failures with misleading falls of intraoperative parathyroid hormone levels. J Endocrinol Invest 2003, 26:1095-1099. Not all patients whose intraoperative PTH levels fall to below 50% of the baseline value after removal of a single adenoma are cured.
62. Gene H, Morita E, Perrier ND, et al.: Differing histologic findings after bilateral and focused parathyroidectomy. J Am Coll Surg 2003, 196:535-540. Differing histologic pictures of single- and multiple-gland disease are presented.
63. Allendorf J, Kim L, Chabot J, et al.: The impact of sestamibi scanning on the outcome of parathyroid surgery. J Clin Endocrinol Metab 2003, 88:3015-3018. The late, great parathyroid surgeon Paul LoGerfo described a largo amount of experience with and without preoperative sestamibi scanning
64. Gallagher SF, Denham DW, Murr MM, et al.: The impact of minimally invasive parathyroidectomy on the way endocrinologists treat primary hyperparathyroidism. Surgery 2003, 134:910-917. The availability of minimally invasive parathyroid surgery is influencing the way in which this disease is being managed.
65. Vassy WM, Nelson HS Jr, Mancini ML, et al.: Minimally invasive parathyroidectomy: how effective is preoperative sestamibi scanning? Am Surg 2003, 69:1090-1094. A discussion is presented about the utility of preoperative sestamibi scanning for the minimally invasive procedure.
66. Sosa JA, Udelsman R: New directions in the treatment of patients with primary hyperparathyroidism. Curr Probl Surg 2003, 40:812-849. Robert Udelsman, one of the pioneers of the minimally invasive parathyroidectomy, provides a perspective of that and other surgical approaches to this disease.
67. Bilezikian JP, Silverberg SJ: Management of asymptomatic primary hyperparathyroidism. N Engl J Med 2004, 350:1746-1751. This article summarizes our current state of knowledge of asymptomatic primary hyperparathyroidism and how this knowledge translates into practical approaches to the patient.
68. Nomura R, Sugimoto T, Tsukamoto R, et al.: Marked and sustained increase in bone density after parathyroidectomy in patients with primary hyperparathyroidism; a six-year longitudinal study with or without parathyroidectomy in a Japanese population. Clin Endocrinol (Oxf) 2004, 60:335-342. After parathyroid surgery, bone density improves, as shown now for a Japanese population.
69. Deaconson TF, Wilson SD, Lemann J: The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery 1987, 215:241-251.
70. Vestergaard P, Mosekilde L: Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 2003, 327:530-534. From a large data set, this paper describes outcomes of parathyroid surgery that have not elusive.
71. Vestergaard P, Mosekilde L: Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism: a controlled cohort study. J Intern Med 2004, 255:108-118. Also from the Danish data set, this paper illustrates the reduction in risk of surgery after successful parathyroid surgery. The patients referred for surgery appear to have more active primary hyperparathyroidism. Whether these results would be applicable to a population with milder primary hyperparathyroidism cannot be determined from this study.
72. Silverberg SJ, Shane E, Jacobs TP, et al.: Primary hyperparathyroidism: 10-year course with or without parathyroid surgery. N Engl J Med 1999, 341:1249-1255.
73. Parfitt AM, Rao DS, Kleerekoper M: Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res 1991, 6(suppl 2):S97-S101.
74. Dawson-Hughes B, Stern DT, Shipp CC, et al.: Effect of lowering dietary calcium intake on fractional whole body calcium retention. J Clin Endocrinol Metab 1998, 67:62-68.
75. Barger-Lux MJ, Heaney RP: Effects of calcium restriction on metabolic characteristics of premenopausal women. J Clin Endocrinol Metab 1993, 76:103-107.
76. Insogna KL, Mitnick ME, Stewart AF, et al.: Sensitivity of the parathyroid hormone-1,25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism. N Engl J Med 1985, 313:1126-1130.
77. Locker FG, Silverberg SJ, Bilezikian JP: Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 1997, 102:543-550.
78. Marcus R: The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Min Res 2002, 17(suppl 2):N146-N149.
79. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 228:321-333.
80. Rubin MA, Lee KH, McMahon DJ, et al.: Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88:1174-1178. In the wake of the Women's Health Initiative, the reluctance to use estrogens is pervasive, including its potential use in the conservative management of primary hyperparathyroidism. In this article, Rubin et al. show in concept that the selective estrogen receptor modulator raloxifene can lower the serum calcium and bone markers in primary hyperparathyroidism.
81. Shane E, Baquiran DC, Bilezikian JP: Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 1981, 95:23-27.
82. Hassani S, Braunstein GD, Seibel MJ, et al.: Alendronate therapy of primary hyperparathyroidism. Endocrinologist 2001, 11:459-464.
83. Rossini M, Gatti D, Isaia G, et al.: Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001, 16:113-119.
84. 82b Parker CR, Blackwell PJ, Faibairn KJ, et al.: Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 2002, 87:4482-4489.
85. Chow CC, Chan WB, Li JKY, et al.: Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88:581-587. This study is a well-designed, randomized clinical trial of alendronate in primary hyperparathyroidism. It is clear that alendronate can increase bone density in this disorder.
86. Kahn AA, Bilezikiam JP, Kung AWC, et al.: Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89:3319-3325. This is another well-designed, randomized, placebo-controlled clinical trial of alendronate in primary hyperparathyroidism. The study is unique in that it was carried out for 2 years. Alendronate increases bone density but does not alter serum calcium or PTH levels.
87. Reasner CA, Stone MD, Hosking DJ, et al.: Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993, 77:1067-1071.
88. Brown EM, Pollak M, Seidman CE: Calcium ion sensing cell surface receptors. N Engl J Med 1995, 333:234-240.
89. Falchetti A: Calcium agonists in hyperparathyroidism. Expert Opin Investig Drugs 2004, 13:229-244. This is a useful review of the current knowledge of calcimimetics in states of excess PTH.
90. Silverberg SJ, Marriott TB, Bone HG III, et al.: Short term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism. N Engl J Med 1997, 307:1506-1510.
91. Shoback DM, Bilezikian JP, Turner SA, et al.: The calcimimetic AMG 073 normalizes serum calcium in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88:5644-5649. The calcimimetic cinacalcet is able to reduce the serum calcium to normal in most patients with primary hyperparathyroidism, as shown in this careful study by Shoback et al.